Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $151,000.

  • Tango Therapeutics' Capital Expenditures rose 31.30% to $151,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $950,000, marking a year-over-year increase of 10.98%. This contributed to the annual value of $754,000 for FY2024, which is 50.59% down from last year.
  • Latest data reveals that Tango Therapeutics reported Capital Expenditures of $151,000 as of Q3 2025, which was down 75.80% from $624,000 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Capital Expenditures ranged from a high of $3.3 million in Q3 2022 and a low of $16,000 during Q3 2023.
  • Over the past 3 years, Tango Therapeutics' median Capital Expenditures value was $195,000 (recorded in 2024), while the average stood at $282,364.
  • As far as peak fluctuations go, Tango Therapeutics' Capital Expenditures surged by 846.06% in 2022, and later slumped by 99.51% in 2023.
  • Over the past 5 years, Tango Therapeutics' Capital Expenditures (Quarterly) stood at $696,000 in 2021, then spiked by 49.57% to $1.0 million in 2022, then crashed by 78.29% to $226,000 in 2023, then slumped by 45.13% to $124,000 in 2024, then soared by 31.30% to $151,000 in 2025.
  • Its last three reported values are $151,000 in Q3 2025, $624,000 for Q2 2025, and $51,000 during Q1 2025.